CD274 and non-small cell lung carcinoma: This phase 1 trial assesses the safety, antitumor activity, and pharmacokinetics of toripalimab in patients with advanced non–small cell lung cancer (NSCLC) and evaluates the utility of JS311, a novel programmed death cell ligand 1 immunohistochemistry assay.